Literature DB >> 20398071

The need for speed in the management of haemophilia patients with inhibitors.

S Z Salek1, G M Benson, I Elezović, V Krenn, R C R Ljung, M Morfini, E Remor, E Santagostino, B Sørensen.   

Abstract

Rapid control of bleeding is the key to reducing bleeding complications and thereby preserving joint and musculoskeletal function in haemophilia patients with inhibitors. However, this requires early diagnosis following the onset of bleeding and strategies for rapid treatment in an outpatient setting. Overarching themes on the need for speed in managing bleeds in haemophilia patients were examined by a panel of clinicians experienced in managing inhibitor patients and joint disease during the Third Zürich Haemophilia Forum on 8 May 2009. This report summarizes the opinions of the panel on how to achieve rapid bleeding control in inhibitor patients and areas that were identified by the panel for future research or as needing new consensus guidelines. The consensus was that home treatment should be established for haemophilia patients with inhibitors, as it is associated with a faster time to treatment, as well as improvements in the quality of life of patients and their carers. In addition, as improved haemostatic control now allows inhibitor patients to participate in a wider range of physical activities, specific guidelines are required on which types of sport and work are appropriate. It was agreed that clear, systematic approaches are needed for early diagnosis of joint and muscle bleeds in inhibitor patients, which could facilitate rapid treatment. There may be opportunities for exploiting new diagnostic techniques from osteoarthritis to enable earlier diagnosis of haemophilic arthropathy. Overall, it was concluded that greater emphasis should be placed on education and patients' psychological needs, to enable inhibitor patients to cope up more effectively with their disease.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20398071     DOI: 10.1111/j.1365-2516.2010.02265.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Development and psychometric testing of the Hemophilia Well-being Index.

Authors:  Eduardo Remor
Journal:  Int J Behav Med       Date:  2013-12

Review 2.  The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors.

Authors:  Shannon L Meeks; Cindy A Leissinger
Journal:  Haemophilia       Date:  2019-09-05       Impact factor: 4.287

3.  Barriers and perceived limitations to early treatment of hemophilia.

Authors:  Kapil Saxena
Journal:  J Blood Med       Date:  2013-05-16

4.  The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.

Authors:  Steven R Lentz; Savita Rangarajan; Faraizah A Karim; Philip D Andersen; Per Arkhammar; Gabriela Rosu; Johnny Mahlangu
Journal:  Blood Coagul Fibrinolysis       Date:  2017-04       Impact factor: 1.276

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.